Skip to content
Back to feed

Science · med impact

Scalable Production of Lead-212 and Actinium-225 Generators with Fusion Neutrons

A new preprint on arXiv proposes using deuterium-tritium fusion neutron sources to scalably produce the medical isotopes Actinium-225 and Lead-212 for targeted alpha therapies.

By Fusion Energy News Desk·9/18/2026, 6:00:30 AM·2 min read·Fri, 18 Sep 2026 06:00:30 GMT·
Preprint
·✓ Editor-verified
Share

Reported fusion metrics

  • Neutron Source Power

    10 MW

    Power of a conceptual D-T neutron source used for irradiating a Th-230 target to produce Ac-225 precursors.

  • Fusion Operational Time

    2 GWd

    Cumulative deuterium-tritium fusion operations required to produce 250 Ci of Th-229.

Researchers have outlined several neutron- and photon-driven pathways for producing critical medical radioisotopes using fusion energy sources, according to a new preprint posted to arXiv. The paper focuses on creating generator parents for Actinium-225 (${}^{225}$Ac) and Lead-212 (${}^{212}$Pb), two alpha-emitting nuclides with high therapeutic potential but severely limited supply. The proposed methods would utilize the high-energy neutron flux from deuterium-tritium (D-T) fusion reactions to transmute target materials like thorium and protactinium. This approach presents a non-fission-based alternative for isotope production, potentially offering a new economic driver for the development of commercial fusion power plants and dedicated neutron source facilities. Source: arXiv

The most direct route detailed for ${}^{225}$Ac production is the ${}^{230}$Th(n,2n)${}^{229}$Th reaction. The authors calculate that a 10 MW D-T neutron source irradiating a thorium target with a 27% ${}^{230}$Th isotopic fraction for six months would accumulate approximately 250 Curies of ${}^{229}$Th. This quantity of the generator parent, which has a half-life of 7916 years, would be sufficient to supply five million ${}^{225}$Ac dose-equivalents annually at the start of its use. The analysis suggests this level of production requires only about 2 gigawatt-days of cumulative D-T fusion operations, a metric within the operational plans of several near-term fusion pilot plant concepts. The long half-life of ${}^{229}$Th makes it a durable, long-term asset for medical supply chains. Source: arXiv

The most direct route detailed for ${}^{225}$Ac production is the ${}^{230}$Th(n,2n)${}^{229}$Th reaction.

For the production of ${}^{212}$Pb, the paper proposes a different pathway involving thermal-neutron irradiation. By irradiating tens of grams of ${}^{230}$Th in a thermal neutron environment, gram quantities of ${}^{232}$U can be produced. This ${}^{232}$U, in turn, serves as a decades-long source for ${}^{228}$Th, the immediate parent of ${}^{212}$Pb. The authors project that this method could generate enough material for millions of ${}^{212}$Pb dose-equivalents per year. This highlights the versatility of using different neutron energy spectra, where fast neutrons from D-T reactions could be moderated to thermal energies to drive specific reactions, expanding the portfolio of isotopes a single fusion facility could produce. Source: arXiv

The preprint also explores alternate production routes starting from more abundant materials like ${}^{232}$Th. Fusion neutrons can convert ${}^{232}$Th into ${}^{231}$Pa at a rate of 1 to 2 tonnes per gigawatt-year of fusion operation. This manufactured ${}^{231}$Pa can then be irradiated in a separate thermal reactor to produce ${}^{232}$U at a rate of up to 0.4 grams per gram of ${}^{231}$Pa. This two-step process, combining a fusion neutron source with a conventional fission reactor, could significantly broaden the feedstock options for medical isotope generation. Such symbiotic applications could provide early revenue streams for the nascent private fusion industry and justify the construction of dedicated high-flux neutron sources before net-energy-gain power plants are fully realized. Source: arXiv

Reporting grounded in coverage from the original publisher read the source .

Weekly newsletter

Fusion Energy Weekly

The week in fusion: breakthroughs, companies, and capital — in your inbox. Free, every Monday.

Primary sources

Editorial standards: Fusion Energy News dispatches are compiled from primary filings, peer-reviewed papers, and on-the-record statements. Corrections: corrections@fusionenergynews.com · public log

More on Science

Letters to the editor(0)

Sign in to write a letter

No letters yet. Be the first to write one.